ESMO 2026
Presentations Supported by Bayer
October 23-27, 2026
Agenda of oral and poster presentations at the 2026 European Society of Medical Oncology (ESMO) Annual Meeting
Please see below to download a PDF for each presentation and view a video (where applicable). Access for each publication will be available after the congress presentation.
Please select a compound to navigate to all related publications.
DAROLUTAMIDE
Darolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: interim analysis of an international, placebo-controlled, randomised phase 3 trial (DASL-HiCaP; ANZUP1801)
Date/Time: October 24, 2026 | 17:42-17:54 CEST
Session: Presidential Symposium I
Type: Oral
Presenting Author: Tamim Niazi
Presentation Number: LBA4
Darolutamide + ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: subgroup analyses from the phase 2 ARASEC study
Date/Time: October 23, 2026 | 15:15 – 16:00 CEST
Session: Metastatic prostate cancer
Type: Poster
Presenting Author: Neal D. Shore
Poster #: 2242P
Prostate-specific antigen (PSA) impact on metastatic hormone-sensitive prostate cancer outcomes with darolutamide plus androgen deprivation therapy (ADT) in ARASEC
Date: October 23, 2026
Session: Metastatic prostate cancer
Type: ePoster
Presenting Author: Mark A. Preston
Poster #: 2374eP
Real-world DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): Results from the European population at prespecified interim analysis 4 (IA4)
Date: October 23, 2026
Session: Localised and locally advanced prostate cancer
Type: ePoster
Presenting Author: Alberto Briganti
Poster #: 2055eP
Darolutamide (DARO) and enzalutamide (ENZA) in the real-world (RW): Extended Survival and Treatment outcomes in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): DEAR-EST
Date: October 23, 2026
Session: Localised and locally advanced prostate cancer
Type: ePoster
Presenting Author: Daniel J. George
Poster #: 2062eP
Real-world use and tolerability of androgen receptor inhibitors in patients with metastatic prostate cancer (mPC) who are androgen pathway modulation–naïve/sensitive (APMN/S)
Date: October 23, 2026
Session: Metastatic prostate cancer
Type: ePoster
Presenting Author: Lorelei A. Mucci
Poster#: 2359eP
Real-world Outcomes of Darolutamide (daro) and androgen deprivation therapy (ADT), with or without Docetaxel (ROAD), in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An observational study
Date: October 23, 2026
Session: Metastatic prostate cancer
Type: ePoster
Presenting Author: Amit Bahl
Poster #: 2391eTiP
Darolutamide vs Abiraterone Triplet Therapy and Survival in U.S. Veterans with Newly Diagnosed Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Date/Time: October 23, 2026 | 15:15 – 16:00 CEST
Session: Metastatic prostate cancer
Type: Poster
Presenting Author: Nathanael Fillmore
Poster #: 2297P
Clinical characteristics, drug-drug interaction risk, and outcomes of darolutamide and rezvilutamide triplet therapy in Chinese patients with metastatic hormone‑sensitive prostate cancer
Date: October 23, 2026
Session: Metastatic prostate cancer
Type: ePoster
Presenting Author: Mingli Luo
Poster #: 2371eP
Long-term Patient-reported and Objective Cognitive Effects of Darolutamide vs Enzalutamide in ARACOG (AFT-47)
Date/Time: October 23, 2026 | 15:15 – 16:00 CEST
Session: Metastatic prostate cancer
Type: Poster
Presenting Author: Daniel Kwon
Poster #: 2280P
Genetic Dementia Risk and Androgen Receptor (AR) Therapy-associated Cognitive Effects (ARTACE) Results from AFT-47, a Randomized Comparison of Darolutamide (DAR) and Enzalutamide (ENZ)
Date/Time: October 23, 2026 | 15:15 – 16:00 CEST
Session: Metastatic prostate cancer
Type: Poster
Presenting Author: Charles J. Ryan
Poster #: 2244P
Genomic biomarkers of response to Extreme Bipolar Androgen Therapy (BAT) alternating darolutamide and testosterone Cypionate in patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - ExBAT Trial (LACOG 0620)
Date/Time: October 23, 2026 | 15:15 – 16:00 CEST
Session: Metastatic prostate cancer
Type: Poster
Presenting Author: Diogo Assed Bastos
Poster #: 2259P
ProBio de-escalation: Darolutamide monotherapy versus ADT plus darolutamide in ctDNA-undetectable metastatic hormone-sensitive prostate cancer
Date: October 23, 2026
Session: Metastatic prostate cancer
Type: ePoster
Presenting Author: Henrik Gronberg
Poster #: 2376eTiP
Baseline patient characteristics according to ctDNA detectability in ProBio: A ctDNA-driven platform trial for metastatic hormone-sensitive prostate cancer
Date: October 23, 2026
Session: Metastatic prostate cancer
Type: ePoster
Presenting Author: Bram De Laere
Poster # 2310eP
DARO-LIPID (ANZUP2205): A randomised phase 2 study of sphingosine kinase inhibitor (opaganib) with darolutamide in poor prognostic metastatic castration resistant prostate cancer based on a circulating lipid biomarker, PCPro
Date: October 23, 2026
Session: Metastatic prostate cancer
Type: ePoster
Presenting Author: Lisa G. Horvath
Poster #: 2384eTiP
Disentangling the association between age and overall survival in an international cohort of patients with advanced prostate cancer
Date/Time: October 23, 2026 | 15:15 – 16:00 CEST
Session: Metastatic prostate cancer
Type: Poster
Presenting Author: Hannah E. Guard
Poster #: 2287P
Thriving despite metastatic prostate cancer: quality of life clustering in an international cohort
Date/Time: October 23, 2026/15:15 – 16:00 CEST
Session: Metastatic prostate cancer
Type: Poster
Presenting Author: Colleen B McGrath
Poster #: 2290P
RADIUM-223
Radium-223 in metastatic castration-resistant prostate cancer: real-world treatment patterns and overall survival by line of therapy in Spain (PROFIT study)
Date/Time: October 23, 2026 | 15:15 – 16:00 CEST
Session: Metastatic prostate cancer
Type: Poster
Presenting Author: Pablo Alvarez Ballesteros
Poster #: 2230P
Impact of enzalutamide-related drug–drug interactions on adverse events in the EORTC 1333-GUCG PEACE-3 trial
Date/Time: October 23, 2026 | 15:15 – 16:00 CEST
Session: Metastatic prostate cancer
Type: Poster
Presenting Author: Mehdi Bsilat
Poster #: 2245P
Longitudinal ctDNA tumor fraction (TF) as a prognostic biomarker in bone-dominant metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 ± olaparib: Results from the phase 2 COMRADE trial
Date/Time: October 23, 2026 | 15:15 – 16:00 CEST
Session: Metastatic prostate cancer
Type: Poster
Presenting Author: Rana McKay
Poster #: 2232P
Baseline genomic landscape and disease burden correlates in bone-metastatic castration resistant prostate cancer: Results from the phase 2 COMRADE trial of radium-223 ± olaparib
Date: October 23, 2026
Session: Metastatic prostate cancer
Type: ePoster
Presenting Author: Rana McKay
Poster #: 2324eP
225-Ac-PSMA-TRILLIUM
Multiparametric assessment of xerostomia following Actinium-225 (225Ac)-PSMA-Trillium (225Ac Felivotide Mopaxetan) therapy for metastatic castration-resistant prostate cancer
Date/Time: October 23, 2026| 15:15 – 16:00 CEST
Session: Metastatic prostate cancer
Type: Poster
Presenting Author: Sebastien J. Hotte
Poster #: 2270P
LAROTRECTINIB
Long-term efficacy and safety of larotrectinib in patients with TRK fusion thyroid cancer: An updated analysis
Date/Time: October 26, 2026 | 12:00 – 12:45 CEST
Session: Head and neck cancer, excluding thyroid
Type: Poster
Presenting Author: Marcia S. Brose
Poster #: 1591P
Long-term efficacy and safety of larotrectinib in patients with TRK fusion solid tumours: NAVIGATE final analysis
Date/Time: October 23, 2026 | 15:15 – 16:00 CEST
Session: Developmental therapeutics
Type: Poster
Presenting Author: Alexander Drilon
Poster #: 1074P
Real-world study of larotrectinib in patients with TRK fusion solid tumours: ON-TRK updated analysis
Date/Time: October 23, 2026 | 15:15 – 16:00 CEST
Session: Developmental therapeutics
Type: Poster
Presenting Author: Jonathan C. Trent
Poster #: 1063P
Real-world outcomes of Larotrectinib in Solid Tumors with Tropomyosin Receptor Kinase Fusion (GETNE S2411 / SPAINTRK)
Date: October 23, 2026 | 15:15 - 16:00 CEST
Session: Developmental therapeutics
Type: Poster
Presenting Author: Jorge Hernando
Poster #: 1070P
SEVABERTINIB
SOHO-01: Updated efficacy and safety of sevabertinib in advanced HER2-mutant NSCLC, including first-line patients (pts) and those with active brain metastases
Date/Time: October 26, 2026/12:00 – 12:45 CEST
Session: NSCLC, metastatic
Type: Poster
Presenting Author: Xiuning Le
Poster #: 2712P
Molecular profile, treatment patterns, and real-world outcomes in HER2-mutant NSCLC: Results from the AACR Project GENIE Registry
Date/Time: October 26, 2026/12:00 – 12:45 CEST
Session: NSCLC, metastatic
Type: Poster
Presenting Author: Brian Piening
Poster #: 2696P
REGORAFENIB
REFINE IO study of systemic therapies in patients (pts) with unresectable hepatocellular carcinoma (uHCC) following first-line (1L) immune checkpoint inhibitor (ICI) combination therapy
Date: October 23, 2026
Session: Hepatocellular carcinoma
Type: ePoster
Presenting Author: Mohamed Bouattour
Poster #: 1712eP
The compendium provided by Bayer is a compilation of Presentations Sponsored by Bayer & Presentations from Bayer-supported Investigator-Initiated Research. Copies of presentations obtained from this compendium are for personal use only and may not be reproduced or distributed without permission from The European Society for Medical Oncology (ESMO) and from the authors. The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Reused with permission. © 2026 European Society for Medical Oncology (ESMO). All rights reserved.
For any questions, please contact Medical Information at 1-888-84-BAYER (1-888-842-2937), or visit go.bayer.com/vPIR
© 2026 Bayer. All rights reserved. Bayer and the Bayer Cross are registered trademarks of Bayer. 100 Bayer Boulevard, PO Box 915, Whippany, NJ 07981 USA. 10/26
MA-M_DAR-US-0430-1
MA-M_DAR-US-0431-1